WARMINSTER, Pa., May 04, 2020 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its first quarter financial results, conference call and webcast for Monday, May 11, 2020. The schedule for the press release and conference call/webcast are as follows:
|•||Q1 2020 Press Release:||May 11, 2020 at 6:00 a.m. ET|
|•||Q1 2020 Conference Call/Webcast:||May 11, 2020 at 8:00 a.m. ET|
|•||Domestic Dial-In Number:||(866) 393-1607|
|•||International Dial-In Number:||(914) 495-8556|
|•||Conference ID Number:||2993486|
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID 2993486.
Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.
Investors and Media
William H. Collier
President and CEO
Investor Relations Consultant